GlassScriptPhysician profile
Joseph H Leaman
NPI 1487095980
$688.88
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $484 · 2020: $13.40 · 2021: $191.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $120.83 | 2019 | |
| Boston Scientific Corporation | $95.98 | 2021 | |
| Medtronic, INC. | $95.34 | 2021 | |
| Lilly USA, LLC | $71.57 | 2019 | |
| Shire North American Group INC | $61.02 | 2019 | |
| Acorda Therapeutics, INC | $58.26 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $41.95 | 2019 | |
| Pfizer INC. | $32.34 | 2019 | |
| Merck Sharp & Dohme LLC | $24.53 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $17.77 | 2019 | |
| Sanofi Pasteur INC. | $16.80 | 2019 | |
| Novo Nordisk INC | $14.99 | 2019 | |
| Sunovion Pharmaceuticals INC. | $13.40 | 2020 | |
| Zyla Life Sciences, INC. | $12.68 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $11.42 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Leaman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.